- Multi-target Drug Discovery for Cancer Therapy: A Contemporary Review. [Journal Article]Recent Pat Anticancer Drug Discov. 2026 Aug 25. [Online ahead of print]RP
- CONCLUSIONS: MKIs and bispecific antibodies represent transformative modalities in modern oncology, supported by robust clinical evidence and extensive patent activity.
- Publisher Full Text (DOI)
- Halofuginone Affects the miR-34c-5p/MAP2K1 Axis Involved in the Development of Colorectal Cancer. [Journal Article]Recent Pat Anticancer Drug Discov. 2026 Jul 24. [Online ahead of print]RP
- CONCLUSIONS: Taken together, our study revealed that the miR-34c-5p/MAP2K1 axis is involved in the development and progression of human CRC and may provide novel insights into the prevention and treatment of CRC. This work also provides a brief overview of several recently issued patents.
- Publisher Full Text (DOI)
- CircSERPINE2 Induces Platinum Resistance in Ovarian Cancer via the miR-513a-5p/miR-526b-3p/SEMA7A Axis. [Journal Article]Recent Pat Anticancer Drug Discov. 2026 Jul 23. [Online ahead of print]RP
- CONCLUSIONS: CircSERPINE2 promotes platinum resistance in OC cells and induces an immunosuppressive environment through the miR-513a-5p/miR-526b-3p/SEMA7A axis, highlighting its potential as a target for overcoming platinum resistance in OC.
- Publisher Full Text (DOI)
- Innovations in Diagnosis Immunotherapy and Combination Therapy of Prostate Cancer: A Patent-driven Analysis. [Journal Article]Recent Pat Anticancer Drug Discov. 2026 Jul 22. [Online ahead of print]RP
- CONCLUSIONS: The novel immunotherapy approaches utilized for PC comprised immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4 inhibitors), Vaccines, and Adoptive Cell Therapy (CAR-T Cells). Similarly, targeted therapy includes Androgen Receptor Signaling Inhibitors, PARP Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors, Tyrosine Kinase Inhibitors (TKIs), and DNA Repair Pathway Targeting Agents, etc. Conclusion: Recent innovations in biomarkers help in the early diagnosis of PC. The advanced stage of PC is well-treated with either single Immunotherapy, targeted therapy, or combinations of both for extending patient survival and hope.
- Publisher Full Text (DOI)
- Pioneering Paclitaxel Delivery: Next-generation Protein Nanocarriers for Transformative Cancer Therapy. [Journal Article]Recent Pat Anticancer Drug Discov. 2026 Jul 21. [Online ahead of print]RP
- CONCLUSIONS: Next-generation protein-based nanocarriers are a unique way to deliver paclitaxel. They have a greater therapeutic index and lead to better patient outcomes. There is a lot of optimism for precision oncology as these biocompatible technologies continue to be improved and used in clinical settings.
- Publisher Full Text (DOI)
- Lomitapide as a Novel Therapeutic Agent in Breast Cancer: Mechanism and Potential Implications. [Journal Article]Recent Pat Anticancer Drug Discov. 2026 Jul 21. [Online ahead of print]RP
- CONCLUSIONS: Lomitapide is a novel repurposed agent for breast cancer treatment. ER-α and PPARγ are potential therapeutic targets.
- Publisher Full Text (DOI)
- Innovative Therapeutic Strategies for Hormone-sensitive Breast Cancer: A Patent Landscape Review. [Journal Article]Recent Pat Anticancer Drug Discov. 2026 Jul 21. [Online ahead of print]RP
- CONCLUSIONS: This review describes current patent-driven innovations in hormone-sensitive breast cancer, highlighting the focus on precision systemic therapies and combination strategies for advanced disease. However, limited attention to the management of endocrine-related adverse effects reveals a critical unmet need for future research and technological development.
- Publisher Full Text (DOI)
- Uncovering the Underlying Mechanism of Clotrimazole against Ovarian Cancer by Transcriptomics and Experimental Investigations. [Journal Article]Recent Pat Anticancer Drug Discov. 2026 Jul 15. [Online ahead of print]RP
- CONCLUSIONS: CTZ is a promising therapeutic agent and may serve as a novel potent agent for ovarian cancer treatment. Its antitumor effects are at least partially mediated via the inhibition of the HER-2/PI3K/AKT signaling pathway.
- Publisher Full Text (DOI)
- Molecular Mechanisms and Senescence Signatures in Cervical Squamous Cell Carcinoma: Insights from Transcriptomic and Single-cell Analyses. [Journal Article]Recent Pat Anticancer Drug Discov. 2026 Jul 15. [Online ahead of print]RP
- CONCLUSIONS: This study demonstrated both the promoting and suppressive roles of senescence in CESC and identified potential therapeutic targets, offering hope for improved outcomes in high-risk patients from low-resource regions.
- Publisher Full Text (DOI)
- Cuproptosis-related Gene SLC31A1 Correlates with M2 Macrophage Infiltration and Serves as a Potential Therapeutic Target in Glioma: A Comprehensive Analysis of 1573 Samples from TCGA and CGGA Databases. [Journal Article]Recent Pat Anticancer Drug Discov. 2026 Jul 10. [Online ahead of print]RP
- CONCLUSIONS: This study provides basic evidence that regulating cellular copper levels by targeting SLC31A1 is a feasible and patented therapeutic strategy. The high expression of SLC31A1 could promote the infiltration of M2 macrophages in glioma.
- Publisher Full Text (DOI)
- Selenium Supplementation in Children and Adolescents Undergoing Cancer Treatment: An Analysis of the Inflammatory Profile and the Expression of Antioxidant Regulators. [Journal Article]Recent Pat Anticancer Drug Discov. 2026 Jul 09. [Online ahead of print]RP
- CONCLUSIONS: This study suggests that selenium supplementation may help modulate inflammatory responses in pediatric oncology patients. While no significant differences were found in Tbars or IL-6, selenium significantly reduced the expression of SEPP1, NFKB, and TRX genes. These results indicate a potential role of selenium in controlling inflammatory gene pathways.
- Publisher Full Text (DOI)
- A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of NHWD-870 HCl in Patients with Lymphoma and Other Advanced Solid Tumors. [Journal Article]Recent Pat Anticancer Drug Discov. 2026 Jul 01. [Online ahead of print]RP
- CONCLUSIONS: NHWD-870 HCl demonstrated manageable, mainly hematologic toxicity and preliminary antitumor activity, supporting further clinical evaluation, particularly in NUT carcinoma and DLBCL.
- Publisher Full Text (DOI)
- Integrated Proteomics and Metabolomics Analysis Provides Insights into Metformin Down-regulating GLUL and SP1 to Inhibit Esophageal Squamous Cell Carcinoma Migration and Invasion. [Journal Article]Recent Pat Anticancer Drug Discov. 2026 Jun 30. [Online ahead of print]RP
- CONCLUSIONS: In summary, metformin may inhibit the migration and invasion of ESCC cells through downregulation of GLUL and SP1, which play important roles in the mechanism of metformin's anti-tumor effects. These findings provide new insights into the therapeutic potential of metformin in the treatment of ESCC.
- Publisher Full Text (DOI)
- SEZ6L2 Promotes Cervical Carcinogenesis by Activating the Wnt Signaling Pathway. [Journal Article]Recent Pat Anticancer Drug Discov. 2026 Jun 24. [Online ahead of print]RP
- CONCLUSIONS: SEZ6L2 promotes CC progression via Wnt/β-catenin signaling and EMT, serving as a prognostic biomarker and therapeutic target. Hsa-miR1271-5p may suppress SEZ6L2 expression, offering novel insights for CC treatment strategies.
- Publisher Full Text (DOI)
- Shengma Biejia Decoction Suppresses Acute Myeloid Leukemia by Regulating Mitochondrial Dynamics through the PI3K/AKT Signaling Pathway. [Journal Article]Recent Pat Anticancer Drug Discov. 2026 Jun 18. [Online ahead of print]RP
- CONCLUSIONS: In conclusion, SMBJD inhibited AML progression in vivo, at least in part, by regulating mitochondrial dynamics through suppression of the PI3K/AKT signaling pathway.
- Publisher Full Text (DOI)